182 related articles for article (PubMed ID: 31239516)
1. KLF4 as a rheostat of osteolysis and osteogenesis in prostate tumors in the bone.
Tassone E; Bradaschia-Correa V; Xiong X; Sastre-Perona A; Josephson AM; Khodadadi-Jamayran A; Melamed J; Bu L; Kahler DJ; Ossowski L; Leucht P; Schober M; Wilson EL
Oncogene; 2019 Jul; 38(29):5766-5777. PubMed ID: 31239516
[TBL] [Abstract][Full Text] [Related]
2. KLF4, A Gene Regulating Prostate Stem Cell Homeostasis, Is a Barrier to Malignant Progression and Predictor of Good Prognosis in Prostate Cancer.
Xiong X; Schober M; Tassone E; Khodadadi-Jamayran A; Sastre-Perona A; Zhou H; Tsirigos A; Shen S; Chang M; Melamed J; Ossowski L; Wilson EL
Cell Rep; 2018 Dec; 25(11):3006-3020.e7. PubMed ID: 30540935
[TBL] [Abstract][Full Text] [Related]
3. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
Akech J; Wixted JJ; Bedard K; van der Deen M; Hussain S; Guise TA; van Wijnen AJ; Stein JL; Languino LR; Altieri DC; Pratap J; Keller E; Stein GS; Lian JB
Oncogene; 2010 Feb; 29(6):811-21. PubMed ID: 19915614
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA LINC00673 silencing inhibits proliferation and drug resistance of prostate cancer cells via decreasing KLF4 promoter methylation.
Jiang Z; Zhang Y; Chen X; Wu P; Chen D
J Cell Mol Med; 2020 Jan; 24(2):1878-1892. PubMed ID: 31881124
[TBL] [Abstract][Full Text] [Related]
5. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
[TBL] [Abstract][Full Text] [Related]
6. Effect of Id1 knockdown on formation of osteolytic bone lesions by prostate cancer PC3 cells in vivo.
Zhang Z; Li K; Zhang X; Fang Z; Xiong W; Chen Q; Chen W; Li F
J Huazhong Univ Sci Technolog Med Sci; 2012 Jun; 32(3):364-369. PubMed ID: 22684559
[TBL] [Abstract][Full Text] [Related]
7. A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.
Fradet A; Sorel H; Depalle B; Serre CM; Farlay D; Turtoi A; Bellahcene A; Follet H; Castronovo V; Clézardin P; Bonnelye E
PLoS One; 2013; 8(9):e75092. PubMed ID: 24069383
[TBL] [Abstract][Full Text] [Related]
8. Downregulated Krüppel‑like factor 4 expression is associated with the aggressiveness of prostate cancer.
Zhang N; Su P; Li X; Xi J; Li X; Xu L
Oncol Rep; 2019 Mar; 41(3):1789-1796. PubMed ID: 30747213
[TBL] [Abstract][Full Text] [Related]
9. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
10. Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer.
Yori JL; Seachrist DD; Johnson E; Lozada KL; Abdul-Karim FW; Chodosh LA; Schiemann WP; Keri RA
Neoplasia; 2011 Jul; 13(7):601-10. PubMed ID: 21750654
[TBL] [Abstract][Full Text] [Related]
11. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
13. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.
Morrissey C; Kostenuik PL; Brown LG; Vessella RL; Corey E
BMC Cancer; 2007 Aug; 7():148. PubMed ID: 17683568
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration.
Wang J; Place RF; Huang V; Wang X; Noonan EJ; Magyar CE; Huang J; Li LC
Cancer Res; 2010 Dec; 70(24):10182-91. PubMed ID: 21159640
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
16. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
[TBL] [Abstract][Full Text] [Related]
18. Krüppel-like factor 4 mediates lysophosphatidic acid-stimulated migration and proliferation of PC3M prostate cancer cells.
Shin SH; Kwon YW; Heo SC; Jeong GO; Kim BR; Seo EJ; Kim JH
Exp Mol Med; 2014 Jul; 46(7):e104. PubMed ID: 24993134
[TBL] [Abstract][Full Text] [Related]
19. miR-148-3p and miR-152-3p synergistically regulate prostate cancer progression via repressing KLF4.
Feng F; Liu H; Chen A; Xia Q; Zhao Y; Jin X; Huang J
J Cell Biochem; 2019 Oct; 120(10):17228-17239. PubMed ID: 31104329
[TBL] [Abstract][Full Text] [Related]
20. Small extracellular vesicles deliver osteolytic effectors and mediate cancer-induced osteolysis in bone metastatic niche.
Ma Q; Liang M; Wu Y; Dou C; Xu J; Dong S; Luo F
J Extracell Vesicles; 2021 Feb; 10(4):e12068. PubMed ID: 33659051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
